新型コロナウイルス感染症(COVID-19)ワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Novel coronavirus [COVID-19] vaccines - Global vaccine commercial opportunity assessment, global market forecast
◆商品コード:VAZ2006003
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2020年5月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (>250 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD10,995 ⇒換算¥1,143,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

The novel coronavirus, SARS-CoV-2 emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases among stallholders at a seafood wholesale market. The resulting respiratory disease, later referred to as COVID-2019, was designated by the World Health Organisation (WHO) a Public Health Emergency of International Concern (PHEIC) on the 30th January 2020 and later a global pandemic by March 11th, 2020.
COVID-19 has affected ~215 countries/territories with greater than 5.8 million confirmed cases and over 360 thousand deaths (as of 29th May 2020), mainly in the elderly and those with chronic underlying conditions. It is predicted that a large proportion of the global population will be infected with SARS-CoV-2 causing further excess morbidity, mortality and substantial economic loss. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV (2012), SARS-CoV-1 (2003) and the endemic human betacoronaviruses OC43 and HKU1 which cause the common cold.

There is no specific treatment for COVID-19 nor widespread immunity. Numerous efforts are now underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2. For vaccines, the Coalition of Epidemic Preparedness Innovations (CEPI) is helping fund candidates including the frontrunners being developed by Moderna Therapeutics, Pfizer (BioNTech), Inovio Pharmaceuticals, and University of Oxford/AZ which have recently entered Phase I or Phase I/II clinical testing. Other clinical stage vaccine programs are underway in China e.g. Sinovac Antivirals e.g. remdesivir and other agents are beginning to make headway although, for some, the scientific validity is being questioned due to a lack of well controlled studies.

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>250 slides) and 2 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic novel coronavirus vaccine to 2045. The model has three detailed and fully adjustable deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East*. ‘At risk’ populations or identified target segments (based on latest understanding) are included. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *Some are rolled up, other scenarios are global – all countries

THIS PRODUCT IS A SUMMARY PRESENTATION (>250 slides, .pdf form) + 2 x FORECAST MODEL(s) (.xls)

https://www.vaczine-analytics.com/VAMV086_TOC_200501_novel_coronavirus_COVID-19_vaccines_global_market_forecast.pdf

【レポートの目次】

PRODUCT CONTENTS:
Published May 2020 (CAT No: VAMV086)
****This product is a summary presentation (.pdf), 1 x forecast models (.xls)
Contents – Summary presentation (.pdf)1
Contents
Author’s notes
Executive summary
[SECTION 1] Novel coronavirus vaccines: key model outputs
[SECTION 2] Novel coronavirus: disease background
[SECTION 3] Novel coronavirus: the 2019/2020 global pandemic
[SECTION 4] Novel coronavirus: background to lung antiviral immunity and host response
[SECTION 5] Novel coronavirus: R&D pipeline and competitor activity
[SECTION 6] Novel coronavirus: modelling commercial potential
[SECTION 7] Novel coronavirus: case studies to pandemic planning
References/bibliography
About VacZine Analytics
Disclaimer
PAGES: >250 slides fully referenced/sourced. Available in .pdf form
Contents – 2 x vaccine demand models (MS Excel-based)
Worksheets = >100 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[新型コロナウイルス感染症(COVID-19)ワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆